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Abstract
Background: Neuroinflammation occurs as a result of microglial activation in response to invading micro-
organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings,
Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent
release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and
interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in
lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the
anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of
Klf4.
Methods: For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500
ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1
expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For
in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of
lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4,
cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using
immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different
conditions.
Results: Our findings suggest that honokiol can substantially downregulate the production of proinflammatory
cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol
downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these
cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol.
Conclusions: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner.
Introduction
Microglia, the resident macrophages of the central ner-
vous system (CNS), are amongst the most important
cells of innate immunity within this organization and
become activated in response to pathological stimuli,
such as endotoxins and other insults to the CNS [1,2].
Activated microglia respond by secreting proinflamma-
tory cyto-chemokines such as macrophage chemoattrac-
tant protein-1 (MCP-1), TNF-a and IL-6 as well as
proinflammatory enzymes such as inducible nitric oxide
synthase (iNOS) and cyclooxygenase-2 (Cox-2) [3-6].
These exaggerated responses by microglia can result in
neuronal damage [7] that can be detrimental to normal
CNS functions [1]. Microglial inflammation is also
observed in several neurodegenerative diseases including
Alzheimer’s disease [8], Parkinson’s disease and multiple
sclerosis [9,10]. Understanding the molecular mechan-
isms of microglial activation and targeting the key
players of inflammation within microglia are essential in
designing therapeutic strategies to deal with inflamma-
tory conditions of the CNS.
Phospho-nuclear factor-B( p N F - B) is one of the
most studied transcription factors for inflammatory
pathways and is attributed with the upregulation of
these proinflammatory cytokines [5,6]. In addition to
pNF-B, zinc finger transcription factor Krüppel-like
factor 4 (Klf4) has been reported to play a key role in
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[11-16] alongside its role in cellular growth and differen-
tiation in the epithelial lining of the gut and skin
[17,18]. More recently, our laboratory has shown that
Klf4 is important in mediating the upregulation of these
proinflammatory cytokines in microglial cells [19]. We
observed a significant increase in the expression of total
as well as nuclear Klf4 in microglial cells upon lipopoly-
saccharide (LPS) treatment in a time-dependent manner.
Upon LPS treatment to BV-2 cells, Klf4 also interacted
with the iNOS promoter, which was confirmed by elec-
trophoretic mobility shift assay studies. During this
study, we also observed that siRNA-mediated knock-
down of Klf4 resulted in a significant reduction in the
levels of these cytokines and proinflammatory enzymes.
In addition, we found that Klf4 potentially interacted
with pNF-Bi nr e s p o n s et oL P S ,s u g g e s t i n gt h a tt h e
two transcription factors may be equally important in
regulating the downstream proinflammatory markers of
microglial activation. It is quite likely that the proin-
flammatory actions of Klf4 are associated with its inter-
action with pNF-B. Since most studies have focused on
t h er o l ep l a y e db yp N F - B in mediating inflammation,
our main focus was to evaluate the inflammatory poten-
tial of Klf4. Our previous studies confirmed that Klf4 is
a key transcription factor in modulating inflammation.
We therefore wanted to investigate whether Klf4 can be
a potential target for anti-inflammatory agents such as
honokiol (HNK).
HNK is a biphenolic anti-inflammatory agent isolated
from the barks of stems and roots of various Magnolia
species and used as a traditional herbal medicine [20].
HNK possesses neuroprotective [21], anti-cancerous
[22,23] and anti-inflammatory properties [24,25]. There
is plenty of literature about the anti-inflammatory roles
of HNK in dendritic cells [26], macrophages [27] and
several other cellular systems [28-32]. It is reported that
the anti-inflammatory actions of HNK in LPS-mediated
inflammation act via p38, extracellular signal-regulated
kinases 1/2 (ERK1/2) and c-Jun N-terminal kinases 1/2
(JNK1/2) pathways [27]. Recently, a study focusing on
t h eu s eo fH N Ko ng l i o s a r c o m ar e v e a l e dt h a ti tc a n
easily cross the blood-brain barrier and blood-cere-
brospinal fluid barrier [22], which makes it a drug of
choice for CNS disorders. Moreover, HNK does not
antagonize the binding of LPS to its receptors and does
not alter the surface expression of CD14 or toll-like
receptor 4 [27]. In addition, HNK also inhibits cytotoxi-
city induced by LPS in RAW264.7 macrophage cells
[25]. Whether HNK treatment modulates Klf4 expres-
sion upon LPS treatment and decreases microglial acti-
vation stimulation has never been studied. Therefore,
this study focuses on understanding the role of HNK in
modulating the expression of Klf4 as well as LPS-
induced neuroinflammation. Our current study shows
that HNK downregulates the expression of Klf4 and
pNF-B and suppresses the overall expression of iNOS
and Cox-2 as well as MCP-1, IL-6 and TNF-a in LPS-
treated microglia as well as in mouse brain. Our study
highlights Klf4 as a potential target for therapeutic activ-
ities of HNK.
Materials and methods
Cells and culture reagents
Mouse microglial cell line BV-2 was originally obtained
from Dr Steve Levison, University of Medicine and Den-
tistry, New Jersey, USA and maintained in the labora-
tory as previously described [19]. Briefly, BV-2 cells
were grown at 37°C in DMEM supplemented with 5%
sodium bicarbonate (NaHCO3), 10% FBS, penicillin at
100 units/mL and streptomycin at 100 μg/mL. All
reagents related to cell culture were obtained from
Sigma Aldrich, St. Louis, MO, USA unless otherwise
stated. Primary mixed glial cultures were prepared from
postnatal day 0-2 (P0-P2) mouse brains as described
previously [19]. The cells were plated into 75-cm
2 tissue
culture flasks at a density of 2 × 10
5 viable cells/cm
2 in
minimum essential medium supplemented with 10%
FBS, penicillin at 100 units/mL, streptomycin at 100 μg/
mL, 0.6% glucose and 2 mM glutamine. Media were
changed every two to three days after plating. On day
12, when the mixed glial culture was confluent, the
flasks were shaken on an Excella E25 orbital shaker
(New Brunswick Scientific, Edison, NJ, USA) at 250 rpm
for 60 to 75 minutes to dislodge microglial cells which
were then allowed to adhere in bacteriological petri
dishes for 60 to 90 minutes. The adherent cells were
scraped, centrifuged and plated in chamber slides at a
density of 8 × 10
4 viable cells/cm
2, and incubated at 37°
C until the treatment.
Lipopolysaccharide and honokiol treatment
For in vitro experiments, treatment involved a pre-incu-
bation with HNK (dissolved in 1X PBS and dimethyl
sulfoxide (DMSO) in a 1:1 ratio; Sigma Aldrich) for 3
hours in serum-free media and then co-treatment with
LPS (Sigma Aldrich) for an additional 6 hours for reac-
tive oxygen species (ROS) and nitric oxide (NO) genera-
tion for a luciferase assay, or for 12 hours for
immunoblotting, immunocytochemistry and cytokine
bead array (CBA) analysis, under serum-free conditions.
The control cells received only serum-free culture
m e d i aa n dam i x t u r eo fD M S Oa n d1 XP B Si na1 : 1
ratio at the same volume as HNK.
For in vivo experiments, three groups of 6- to 8-week-
old BALB/c mice were injected intraperitoneally with
2.5 or 5 mg/kg body weight of HNK dissolved in 1X
PBS and DMSO in a 1:1 ratio over 12 hours while the
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DMSO in a 1:1 ratio). After 12 hours of HNK adminis-
tration, mice were injected intraperitoneally with 5 mg/
kg body weight of Salmonella enterica LPS dissolved in
1X PBS for an additional 24 hours. Control animals
received the same volume of 1X PBS alone. All the ani-
mals were killed after 24 hours of treatment for tissue
or protein. All experiments were performed according
to the protocol approved by the Institutional Animal
Ethics Committee.
Measurement of reactive oxygen species and nitric oxide
We examined the effects of LPS and HNK + LPS on
microglial cells by determining the levels of ROS as well
as NO. Intracellular ROS generation in control and trea-
ted cells was assessed using the cell permeable, non-
polar hydrogen peroxide-sensitive dye 5-(and-6)-chlro-
methyl-2’,7 ’- dichlorodihydrofluorescein diacetate
(Sigma Aldrich) and the mean fluorescent intensities
(MFIs) were measured on the FL-1 channel on a fluor-
escence-activated cell sorting (FACS) Calibur flow cyt-
ometer (Becton Dickinson, Franklin Lakes, NJ, USA) as
described previously [33]. For NO production, nitrite
generation by BV-2 cells was used as an indicator of
NO release and measured by the Griess reaction as
described previously [19]. The readings were taken at
540 nm using a microplate spectrophotometer (Bio-Rad,
Gladesville, NSW, Australia) and the concentration was
calculated from a sodium nitrite standard reference
curve.
Immunoblotting
For in vitro studies, untreated control and treated BV-2
cells were lysed in buffer containing 1% Triton-X-100,
10 mM Tris(hydroxymethyl)aminomethane-Cl (pH 8.0),
150 mM sodium chloride, 0.5% octylphenoxypolyethox-
yethanol (Nonidet P-40), 1 mM ethylenediaminetetraa-
cetic acid, 0.2% ethylene glycol tetraacetic acid, 0.2%
sodium orthovanadate and protease inhibitor cocktail
(Sigma Aldrich).
For in vivo studies, the whole brain tissues, barring the
olfactory lobes and the cerebellum, from three animals
after 24 hours of LPS administration and untreated mock
controls were dissected and homogenized in 1X PBS with
protease inhibitor. Protein concentrations were deter-
mined using the bicinchoninic assay method and 30 μg
of each protein sample was electrophoresed on a 7.5% to
10% SDS-PAGE and transferred onto a nitrocellulose
membrane. After blocking in 5% skimmed milk in 1X
PBS-Tween-20 (1X PBST) for 4 hours at room tempera-
ture, the blots were incubated in 1X PBST overnight at 4°
C with gentle agitation with either rabbit anti-Klf4
(1:500; Chemicon International, Temicula, CA, USA),
anti-iNOS (1:1,000; Millipore, Billerica, MA, USA), Cox-2
(1:1,000; Millipore), pNF-B (1: 1,000; Ser-536; Cell Sig-
naling Technology, Danvers, MA, USA) and anti-b-actin
(1:10,000; Sigma Aldrich). After five washes in 1X PBST,
blots were then incubated with goat anti-rabbit horserad-
ish peroxidase (1:5,000; Vector Laboratories, Burlingame,
CA, USA) for 1.5 hours, with agitation. The blots were
developed by using chemiluminescence reagent (Milli-
pore) in ChemiGenius Bioimaging System (Syngene,
Cambridge, UK). The images were captured and analyzed
using the GeneSnap and GeneTools software, respec-
tively, from Syngene. The protein levels were normalized
to b-actin levels.
Luciferase assay
Luciferase reporter gene constructs pGL2-iNOS (kindly
provided by Dr Mark A. Feinberg and Dr Mukesh K.
Jain, Harvard Medical School, Boston, MA, USA; the
construct was originally made by Dr Mark A. Perella,
also Harvard Medical School) [12,34] and pCOX301 (a
kind gift from Dr Manikuntala Kundu, Bose Institute,
Kolkata, India) [35] were used, containing mouse iNOS
promoter region (-1485 to +31 bp) and Cox-2 promoter
region (-891 to +9 bp) cloned upstream of the luciferase
reporter gene in the pGL2-promoter and pGL2-basic
vector, respectively (Promega, Madison, WI, USA). The
luciferase assay was carried out using the luciferase
assay kit (Promega) according to the manufacturer’s
protocol and as described previously [19]. The reading
was taken using a Sirius single tube luminometer (Bert-
hold Detection Systems GmBH, Bad Wildbad, Ger-
many). The luciferase units were measured as relative
luciferase units and these values were normalized to the
amount of protein present in the sample.
Generation of Klf4 construct
Oligonucleotide primers were designed to amplify the
coding sequence of full-length mouse Klf4 cDNA yield-
ing a 1452 bp (1.4 kb) product. The oligonucleotide pri-
mers were as follows: forward primer: 5’-ATGAGGC-
AGCCACCTGGCGA-3’; reverse primer: 5’- TTAAAA-
GTGCCTCTTCATGTGTAA-3’. The amplified product
was then electrophoresed onto 0.8% agarose and the
1452 bp fragment was gel extracted using a Gel Extrac-
tion Kit (Qiagen, Hilden, Germany). The fragment was
then inserted into the pcDNA3.1/V5 His TopoTA
expression vector (Invitrogen, Carlsbad, CA, USA) to
generate a pcDNA3.1-Klf4 (K-10) construct which was
sequenced commercially (ILS Bioservices, Manesar,
India).
Immunochemical studies
For immunocytochemical studies, mouse primary micro-
glial cells were fixed in 4% paraformaldehyde for 20
minutes at 25°C post-treatment and then incubated in
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then incubated with rabbit anti-Klf4 (1:250; Millipore)
overnight at 4°C. Anti-rabbit Alexa fluor 594 secondary
antibody (1:1,000; Vector Laboratories) was used as the
secondary antibody and mounting was carried out with
mounting medium containing 4,6-diamidino-2-phenylin-
dole (DAPI; Vector Laboratories). Images were captured
using a Zeiss Apotome microscope (20× magnification;
Zeiss, Hamburg, Germany). For immunohistochemistry,
LPS-treated and age-matched control BALB/c mice in
sets of three were perfused transcardially with 1X PBS
and isolated whole brains were fixed with 4% parafor-
maldehyde in 1X PBS for 24 hours at 4°C. These were
then kept in 30% sucrose for about 24 to 48 hours at 4°
C or until the tissue was immersed at the bottom of the
tube. The brains were then sectioned on a cryostat and
stained for a marker of activated microglia, Iba1, as
described previously [19]. Briefly, microglia were labeled
with rabbit anti-Iba1 antibody (1:250; Wako, Osaka,
Japan) by incubating the sections overnight at 4°C. After
five washes with 1X PBS, the sections were incubated
with horse anti-mouse fluorescein isothiocyanate (1:250;
Vector Laboratories) for 1.5 hours. The slides were then
mounted with mounting medium containing DAPI and
images were captured using a Zeiss Apotome micro-
scope (40× magnification; Zeiss).
Cytokine bead array
The CBA kit (BD Biosciences, Franklin Lakes, NJ, USA)
was used for the quantitative measurement of cytokine
levels in control, LPS and LPS + HNK conditions. Using
50 μL of mouse inflammation standard and sample dilu-
tions, the assay was performed according to the manu-
facturer’s instructions and analyzed on the FACSCalibur
flow cytometer (Becton Dickinson). Analysis was per-
formed using CBA software that allows the calculation
of cytokine concentrations in unknown lysates as
described previously [19,36]. The levels of cytokines
were measured in picograms per milliliter.
Statistical analysis
Data are represented as the mean ± standard error of
the mean (SEM) from at least three independent experi-
ments. The data generated were analyzed statistically by
paired two-tailed Student’s t-test. P < 0.01 and < 0.05
were considered significant.
Results
Honokiol reduces microglial activation in vitro
Treatment of BV-2 cells with LPS results in microglial
activation that can be measured by the increase in the
levels of the proinflammatory enzymes iNOS and Cox-2
as well as the proinflammatory cyto-chemokines, MCP-
1, IL-6 and TNF-a [19]. TNF-a, an acute phase protein
that is secreted by macrophages and microglia in
response to pathogenic stimuli, MCP-1, known to
recruit inflammatory cells into CNS parenchyma [37]
and IL-6, which has pleotropic functions in the CNS
[38,39], are all cytokines known to increase dramatically
in response to inflammation and CNS injury. We
observed a significant increase in the levels of these
proinflammatory markers after 12 hours of LPS stimula-
tion. For HNK work, we estimated the cell viability
using different doses of HNK (data not shown) and
found that 1 μMa n d1 0μM doses of HNK are non-
toxic doses for in vitro work. We therefore used these
doses for our in vitro experiments. We found that in
LPS + HNK conditions, the levels of these cytokines are
significantly reduced as compared to the LPS alone con-
dition. The levels of iNOS were significantly reduced by
more than two-fold in both 1 μM and 10 μM HNK con-
ditions when compared with LPS alone (1A). However,
there was no dose-dependent decrease in iNOS levels as
the levels of iNOS upon treatment with both 1 μMa n d
10 μM HNK was not significantly different from each
other. There was no significant reduction in the levels
of Cox-2 upon treatment with 1 μM HNK but treatment
with 10 μM HNK significantly reduced the Cox-2 level
in BV-2 cells by 1.5-fold with respect to the LPS-treated
control (1B). We then wanted to see the effect of HNK
on the levels of LPS-induced proinflammatory cytokines
in BV-2 microglial cells. For this study, we carried out
CBA analysis, which revealed a marked reduction in the
levels of MCP-1 (1C), IL-6 (1D) and TNF-a (1E) cyto-
chemokines with respect to LPS-treated conditions.
These observations show for the first time that HNK
has anti-inflammatory properties in activated microglial
cells in vitro. These findings support existing literature
on the anti-inflammatory properties of HNK for periph-
eral inflammation.
Honokiol decreases reactive oxygen species and nitric
oxide generation in response to lipopolysaccharide
treatment in vitro
Generation of ROS and NO by microglial cells in
response to LPS is a key marker for oxidative stress in
these cells. Earlier work has shown the anti-oxidant
properties of HNK in monocytes and macrophages [25].
We therefore measured ROS and NO levels in LPS-trea-
ted microglial cells upon HNK treatment. Our findings
suggest that HNK significantly reduces the production
of both of these stress molecules. While LPS increased
the formation of ROS by more than two-fold within 6
hours of stimulation (2A) as analyzed by measuring the
MFIs using FACS, we observed that there was a signifi-
cant reduction in the levels of ROS upon HNK treat-
ment in a dose-dependent manner. While there was a
reduction by 1.5-fold in ROS levels upon treatment with
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tion with 10 μM HNK (2C), thereby maintaining the
ROS to the control levels (2D).
We also estimated nitrite production in order to mea-
sure NO release by LPS-stimulated BV-2 cells upon
HNK treatment. Similar to our observations with ROS
production, LPS increased generation of nitrite by more
than 2.5-fold in comparison to the untreated control
condition (2E), which was reduced by HNK treatment.
Although the reduction was not significant with 1 μM
HNK dose, we observed a significant decrease in NO
levels with 10 μM HNK dose when compared with the
LPS alone-treated condition (2E). These findings con-
firm that HNK reduces the oxidative stress generated in
BV-2 microglial cells upon LPS stimulation. Reduction
in NO production also supports our observation of a
Figure 1 Effect of honokiol on lipopolysaccharide-stimulated BV-2 cells. Total cellular extract isolated from cells treated with 500 ng/mL of
LPS and different doses of HNK for 12 hours were analyzed by immunoblotting. (A) Significant decrease in iNOS levels upon treatment with 1
μM and 10 μM HNK in LPS-treated cells with respect to LPS alone-treated cells. (B) Significant decrease in the expression of Cox-2 upon
treatment with 10 μM HNK. The graphs represent fold change in protein levels relative to untreated controls. (C-E) CBA analysis of protein
extract from BV-2 cells treated with LPS as well as in LPS + HNK conditions. CBA revealed a significant decrease in BV-2 cells treated with
different doses of HNK in the levels of MCP-1 (C), IL-6 (D) and TNF-a (E) with respect to LPS. Absolute values of cytokines are represented in pg/
mL. Data represent mean ± SEM from three independent experiments performed in duplicate. *P < 0.05 and **P < 0.01 in comparison to LPS-
treated values.
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stimulated cells.
Honokiol suppresses the production of cyclooxygenase-2
and proinflammatory cyto-chemokines in vivo
From our findings so far we know that HNK reduces
LPS-mediated inflammation in vitro where it is shown
to suppress the production of proinflammatory enzymes
as well as cyto-chemokines. In order to confirm whether
HNK can reduce inflammation in vivo in mouse brain
as well, we measured the levels of proinflammatory
cytokines and Cox-2 in LPS-treated mice. While the
levels of all these inflammatory markers were signifi-
cantly elevated in mice administered with LPS alone,
mice that were treated with HNK in addition to LPS
showed a significant 1.5-fold reduction in the levels of
Cox-2 (3A). When we analyzed the brain homogenate
for cytokines, we found that, in LPS-treated mice, the
levels of all these cytokines were elevated significantly
with respect to control-treated mice. A dosage of 5 mg/
kg body weight of HNK significantly reduced the levels
of MCP-1 by about two-fold in mice (3B). Both the
doses of HNK reduced the production of IL-6 by more
than 1.5-fold (3C) and TNF-a by more than 1.4-fold
(3D) with respect to the LPS alone-treated mouse
group. These findings suggest that, in addition to its
anti-inflammatory role in vitro, HNK can reduce inflam-
mation of the CNS.
Honokiol reduces the promoter activity of inducible nitric
oxide synthase and cyclooxygenase-2
It is evident from our studies so far that HNK downre-
gulates the production of iNOS and Cox-2. In order to
confirm whether HNK reduces the promoter activities
Figure 2 Effect of honokiol on reactive oxygen species and nitric oxide generation in lipopolysaccharide-stimulated BV-2 cells.T o t a l
cellular extract and supernatant detected for the levels of ROS and NO in LPS- and HNK-treated cells. Representative FACS plot showing
intracellular ROS production. (A) Increase in the levels of ROS generation upon LPS treatment with respect to untreated control condition. (B, C)
Decrease in ROS generation upon treatment with 1 μM and 10 μM HNK in LPS-stimulated cells. (D) Graph representing the MFI of ROS
generation. (E) Graph representing nitrite concentration in LPS and LPS + HNK conditions. Nitrite is measured in μM quantities. Data represent
mean ± SEM from three independent experiments performed in duplicate. *P < 0.05 and **P < 0.01 in comparison to LPS-treated values.
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assays using pGL2-iNOS and pCOX301 constructs. We
found that while LPS treatment enhanced the promoter
activities of iNOS and Cox-2 by three- and two-fold
respectively, HNK treatment significantly reduced the
promoter activities of both iNOS and Cox-2 (4A, B).
While 1 μM HNK was enough to bring down the
iNOS promoter activity, Cox-2 promoter binding activ-
ity was severely affected with 10 μMH N Ka f t e r6
hours of LPS stimulation. The reduction in promoter
activities of iNOS and Cox-2 upon HNK treatment
suggests that HNK inhibits the binding of transcription
factors to their respective promoters in BV-2 microglial
cells.
Honokiol reduces the expression of Krüppel-like factor 4
and phospho-NF-B in vitro
LPS induces the expression of pNF-B in macrophages
as well as in microglial cells. We have previously shown
that LPS induces both the expression of pNF-B as well
as Klf4 in BV-2 cells and primary microglia [19]. We
wanted to see if HNK downregulates the expression of
these two transcription factors in microglia upon activa-
tion. We found that HNK significantly reduces the
expression of both pNF-B and Klf4 in a dose-depen-
dent manner in BV-2 cells. We have observed a reduc-
tion of 1.4-fold in pNF-Bl e v e l sw i t h1μMH N Kw h i l e
there was about two-fold reduction in its levels when
LPS-treated cells were co-treated with 10 μM HNK (5A)
with respect to LPS alone-treated cells. We found simi-
lar results when we looked at the levels of Klf4. Signifi-
cantly, there was a more than two-fold reduction in the
levels of Klf4 with both 1 μMa n d1 0μMH N Kd o s e s
(5B) with respect to LPS-treated cells. To the best of
our knowledge, this is the first report showing that Klf4
can be downregulated by any anti-inflammatory agent.
The reduction in Klf4 and pNF-B levels confirm
HNK’s anti-inflammatory properties in microglial activa-
tion as both these transcription factors are associated
with proinflammatory activities in these cells.
Figure 3 Levels of cyclooxygenase-2 and proinflammatory cytokines in lipopolysaccharide- and honokiol-treated BALB/c mice. BALB/c
mice administered with different doses of HNK and 5 mg/kg body weight of LPS were analyzed by Cox-2 immunoblotting and CBA analysis. (A)
Decrease in the levels of Cox-2 in mice treated with different doses of honokiol. Graph represents fold change in Cox-2 levels relative to
untreated control condition. (B-D) CBA analysis of brain homogenates from BALB/c mice in different conditions. There was a significant decrease
in the levels of MCP-1 (B), IL-6 (C) and TNF-a (D) in mice treated with different doses of HNK. Absolute values of cytokines are represented in
pg/mL. Data represent mean ± SEM of five animals in each group. *P < 0.05 and **P < 0.01 in comparison to LPS-treated values.
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and phospho-NF-B in vivo
To corroborate our in vitro findings with regards to the
regulation of Klf4 and pNF-B, we estimated the levels
of these two transcription factors in mouse brain upon
treatment with HNK and LPS. Similar to our observa-
tions with BV-2 cells, we found that there was an overall
reduction in the levels of both pNF-Ba n dK l f 4i n
HNK-treated mice when compared to the LPS alone-
treated group. There was a more than 1.5-fold decrease
Figure 4 Inducible nitric oxide synthase and cyclooxygenase-2 promoter assay in response to lipopolysaccharide and honokiol.
Luciferase assay from total protein extracts from pGL2-iNOS and pCOX301 transfected, LPS- and HNK-treated BV-2 cells. (A) Decrease in iNOS
promoter activities upon stimulation with different doses of HNK with respect to LPS-treated condition. (B) Decrease in Cox-2 promoter activities
upon stimulation with 10 μM HNK in comparison to LPS-treated condition. Graphs represent relative luciferase units normalized to protein levels.
Data represent mean ± SEM from three independent experiments performed in duplicate. *P < 0.05 and **P < 0.01 in comparison to LPS-treated
values.
Figure 5 Effect of honokiol on the expression levels of phospho-NF-B and Krüppel-like factor 4 in BV-2 cells. Total cellular extract
isolated from cells treated with 500 ng/mL of LPS and different doses of HNK for 12 hours were analyzed by immunoblotting for Klf4 and pNF-
B levels. (A) Decrease in pNF-B levels upon treatment with different doses of HNK. (B) Significant decrease in Klf4 levels upon treatment with
different doses of HNK. The graphs represent fold change in protein levels relative to untreated controls. Data represent mean ± SEM from three
independent experiments performed in duplicate. *P < 0.05 and **P < 0.01 in comparison to LPS-treated values.
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mice were treated with 2.5 and 5 mg/kg body weight of
HNK (6A, B) with respect to LPS-treated mice. The
r e d u c t i o ni nt h el e v e l so ft h e s e transcription factors is
crucial for controlling inflammation which is induced by
LPS in the brain.
Honokiol reduces Krüppel-like factor 4 expression and
activation of primary microglia
While we have confirmed that Klf4 expression in
response to LPS is suppressed by treatment with HNK in
vitro in BV-2 cells as well as in vivo in BALB/c mice, we
wanted to study whether HNK induces any such changes
in primary microglia. Immunocytochemical studies reveal
that treatment with LPS for 12 hours increased Klf4
expression in primary microglia (7B) with respect to
untreated controls (7A). In LPS-treated primary micro-
glia, we observed elongated microglial processes within
12 hours of LPS treatment, suggesting an activated mor-
phology. However, upon treatment with 10 μM HNK, we
saw a reduction in Klf4 expression in primary microglia
cells and the processes that were extended upon LPS
exposure were markedly reduced (7C). The effect of
HNK on the activation of primary microglia and Klf4
expression supports our previous observations of HNK’s
effect in culture as well as in mice models.
Honokiol reduces microglial activation in mouse cortex
So far, it is clear from our findings that HNK reduces
inflammation in the brain. Whether HNK brings down
microglial activation in the mouse brain was confirmed
by immunohistochemical analysis of the mouse brain
cortex. The group that received LPS alone showed a
marked activation of microglia as shown by an arrow in
8B compared to the untreated control group (8A) after
24 hours of LPS treatment. These activated microglia
show a bushy appearance and have a large number of
activated processes. However, the images from the
mouse brain receiving HNK suggest a marked reduction
in activation of microglia (8C, D). Upon treatment with
2 . 5a n d5m g / k gb o d yw e i g h to fH N K ,t h em i c r o g l i a
exhibited a ‘resting’ morphology similar to that observed
in a control mouse brain. These findings show that
these doses of HNK are effective in reducing microglial
activation in vivo, thereby reducing inflammation in the
mouse brain.
Krüppel-like factor 4 overexpression increases
inflammation and suppresses the anti-inflammatory
activity of honokiol
According to our earlier reports, knockdown of Klf4 in
LPS-treated BV-2 cells decreased inflammation [19]. To
find out whether overexpression of Klf4 can increase
inflammation in these cells and whether it can override
HNK’s anti-inflammatory action of downregulating the
production of proinflammatory enzymes, we transfected
BV-2 cells with pcDNA3.1-Klf4 construct (K-10) and
measured the levels of Klf4, iNOS and Cox-2 in different
conditions. The control cells either received only lipofec-
tamine (untreated condition) or were transfected with
pcDNA3.1-LacZ construct (LacZ) for transfection con-
trol. Upon LPS stimulation in K-10 transfected cells,
Figure 6 Effect of honokiol on the expression levels of phospho-NF-B and Krüppel-like factor 4 in vivo. Brain homogenate from BALB/c
mice treated with different doses of HNK and 5 mg/kg body weight of LPS analyzed by immunoblotting for Klf4 and pNF-B levels. (A)
Significant decrease in the levels of pNF-B in 2.5 as well as 5 mg/kg body weight dose of HNK with respect to LPS-treated mice. (B) Significant
decrease in Klf4 levels in 2.5 as well as 5 mg/kg body weight HNK doses with respect to LPS-control mice. Graphs represent fold change in
protein levels with respect to untreated control condition. Data represent mean ± SEM of five animals in each group. *P < 0.05 and **P < 0.01 in
comparison to LPS-treated values.
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Page 9 of 15there was a significant induction in the levels of Klf4 with
respect to the LPS alone-treated condition (9A). Treat-
ment with 10 μM HNK resulted in a significant reduction
of Klf4 in K-10 + LPS cells. However, the levels of Klf4
were still significantly higher than those observed in the
LPS alone condition. Similar observations were made
when the levels of iNOS and Cox-2 were measured in
these conditions. iNOS and Cox-2 levels increased signif-
icantly in K-10 + LPS cells with respect to the LPS alone
condition, confirming our previous findings that Klf4 is
involved in the upregulation of these proinflammatory
enzymes (9B, C). In addition to these findings, we deter-
mined that treatment with 10 μM HNK did not signifi-
cantly reduce Cox-2 or iNOS levels in K-10 + LPS cells,
which remained significantly higher with respect to the
LPS alone condition (9B, C). While it is clear from this
study that Klf4 promotes inflammation, it is also note-
worthy that Klf4 overexpression suppresses the anti-
inflammatory action of HNK. We can infer from these
findings that the targeting of Klf4 by HNK is a crucial
event required for its anti-inflammatory properties.
Discussion
Inflammation of the CNS is marked by the excessive pro-
duction of numerous proinflammatory cyto-chemokines
including TNF-a,M C P - 1a n dI L - 6i nr e s p o n s et oL P S
[3,4]. Previous reports from our laboratory have suggested
that Klf4 is involved in mediating microglial activation and
the regulation of proinflammatory mediators in response
to LPS [19]. This study revealed HNK for the first time as
an important factor regulating inflammation in microglial
cells in addition to pNF-B, another key player in inflam-
matory pathways. The focus of our study was to determine
whether HNK, a biphenolic compound that can easily
cross the blood-brain barrier [22] and also has a neuropro-
tective role in the brain [40], can reduce microglial activa-
tion and whether these activities are mediated by
regulating Klf4. For our experiments, we induced inflam-
mation in BV-2 cells and BALB/c mice using LPS and
then treated them using HNK, whose anti-inflammatory
role in the CNS has not previously been studied. Our stu-
dies show that HNK significantly reduces microglial acti-
vation and secretion of proinflammatory cyto-chemokines
Figure 7 Effects of honokiol on Krüppel-like factor 4 expression in lipopolysaccharide-treated primary microglia. Primary microglia
isolated from P0-P2 BALB/c mice treated with 500 ng/mL of LPS and 10 μM of HNK were analyzed by immunocytochemistry. (A) Fluorescent
images of untreated primary microglia treated with a sham mixture of 1X PBS and DMSO in a 1:1 ratio. (B) Primary microglia treated with LPS
for 12 hours and (C) LPS-treated primary microglia co-treated with HNK for 12 hours. Images showing the staining for Klf4 (Alexa fluor 594;
Rhodamine channel); DAPI (blue) and merged images (right panel). Scale bar: 20 μm.
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Page 10 of 15Figure 8 Honokiol-mediated reduction in microglial activation in vivo. Cryostat sections from BALB/c mice treated with different doses of
HNK and 5 mg/kg body weight of LPS, analyzed by immunohistochemistry. (A) Fluorescent images of brain section from control mice showing
microglia in their ‘resting’ morphology. (B) Images showing the an increase in the number of ‘activated’ microglia in response to LPS as shown
by an arrow. (C, D) Images from mice treated with 2.5 mg/kg body weight of HNK (C) and 5 mg/kg body weight of HNK (D) showing microglia
with resting stage morphology similar to the control condition, marked by a small arrow. Images show the staining for Iba-1 (fluorescein
isothiocyanate, green), DAPI (blue) and merged images (right panel). Scale bar: 50 μm.
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Page 11 of 15Figure 9 Effect of Krüppel-like factor 4 overexpression on the anti-inflammatory properties of honokiol. Total cellular extract isolated
from cells transfected with K-10 and LacZ constructs and treated with 500 ng/mL of LPS along with different doses of HNK, analyzed by
immunoblotting for Klf4, iNOS and Cox-2. (A) Expression levels of Klf4 in different conditions showing increased expression of Klf4 in LPS-treated
with respect to untreated control as well as a significant increase in Klf4 in K-10 + LPS cells with respect to LPS alone condition. (B) Cox-2
expression showing increased expression under K-10 + LPS as well as HNK-treated K-10 + LPS conditions with respect to LPS alone or control
untreated condition. (C) Expression levels of iNOS showing significant increase in its levels in K-10 + LPS and K-10 + LPS conditions treated with
HNK compared to LPS alone-treated condition. Graphs represent fold change in protein levels with respect to untreated control condition. Data
represent mean ± SEM from three independent experiments performed in duplicate. **P < 0.01 in comparison to LPS-treated values.
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Page 12 of 15in response to LPS; that HNK downregulates both Klf4
and pNF-B in vitro as well as in vivo; and that overex-
pression of Klf4 suppresses the anti-inflammatory proper-
ties of HNK.
Endotoxins such as bacterial LPS can result in systemic
inflammation and induce severe neuroinflammation,
resulting in the production of iNOS and Cox-2 proin-
flammatory enzymes as well as other cytokines including
TNF-a, MCP-1 and IL-6, which are potent mediators of
inflammation in CNS [3,4]. This can be suppressed using
anti-inflammatory agents which usually target pNF-B
pathways. iNOS catalyzes the production of NO, which
can be neurotoxic at high concentrations [41,42]. On the
other hand, Cox-2 catalyzes the production of prosta-
glandins such as prostaglandin E2 from arachidonic acid,
which are then converted to active prostanoids by
synthases [35,43]. The exaggerated production of these
cytokines along with iNOS and Cox-2 can be deleterious
to neuronal health. It is therefore necessary to find tran-
scription factors which regulate their production. It is
well known that, upon stimulation with LPS, pNF-B
binds to iNOS and Cox-2 promoter elements [6,44-46]
and upregulates their production. We have previously
shown that Klf4 also interacts with iNOS and Cox-2 pro-
moter elements in response to LPS in microglial cells
[19]. HNK can induce inflammation via different path-
ways, including p38, ERK1/2 and JNK1/2 as well as the
phosphoinocytide-3 kinase/AKT (protein kinase/AKT)
pathway [27,47], in addition to targeting pNF-B [25,48];
w ep r o p o s et h a tH N Km i g h ta l s od o w n r e g u l a t eK l f 4 ,
thereby regulating iNOS and Cox-2 levels. It is quite
likely that HNK, in addition to reducing pNF-Ba n d
Klf4 expression, may inhibit the interactions between
these two transcription factors upon LPS stimulation as
was reported in our previous study [19]. However, further
studies are required to study this activity of HNK in
microglia. These inhibitory actions of HNK may result in
the overall suppression of the proinflammatory state of
microglia. Our present study shows that HNK not only
inhibits Klf4 and downregulates the production of iNOS
and Cox-2, it also dampens the production of other
proinflammatory cyto-chemokines such as MCP-1, IL-6
and TNF-a as well as generation of NO in microglial
cells in vitro. These properties of HNK are demonstrated
in the schematic diagram representing its mode of action
in LPS-treated microglia (Figure 10).
HNK also suppresses neuroinflammation stimulated by
LPS in the mouse brain and induces the activation of
microglia within the brain cortex of LPS-stimulated mice.
Microglia in HNK + LPS mice resemble the resting state
morphology, clearly showing that HNK does reduce neu-
roinflammation. It would be of interest to understand the
role played by HNK in affecting other cell types of the
brain as well as its underlying molecular mechanisms as
other cell types, including astrocytes, also have been
reported to have neuromodulating properties.
Oxidative stress is an important feature of inflammation
and the role of HNK for its anti-oxidant properties have
been studied in detail in the peripheral system and there is
plenty of literature on its mode of action. Studies on
Figure 10 Schematic showing the possible mode of action of honokiol. LPS stimulation results in the overexpression of Klf4 and pNF-Bi n
microglial cells, which migrate to the nucleus and enhance the promoter activities of proinflammatory genes, thereby resulting in microglial
activation. HNK inhibits the expression of these transcription factors as well as iNOS and Cox-2 promoter activities in LPS-stimulated microglial
cells. HNK also suppresses the production of neuroinflammatory molecules, including TNF-a, MCP-1 and IL-6. In addition, HNK blocks NO
production and ROS generation from activated microglia.
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Page 13 of 15collagen-induced arthritis in mice have shown that HNK
suppresses production of TNF-a and IL-1b along with a
reduction in oxidative damage [49]. Studies on ischemic
injury in rats have shown that HNK can act as a potent
ROS inhibitor by potentially modulating the enzymes in
ROS production, such as myeloperoxidase, Nicotinamide
adenine dinucleotide phosphate oxidase and Glutathione
peroxidase in neutrophils [50,51]. In cerebellar granule
neuronal cells, HNK was found to reverse hydrogen per-
oxide-mediated neurotoxicity [21]. Similarly, HNK admin-
istration resulted in a significant suppression of oxidative
damage in mouse brain treated with N-methyl-d-aspartic
acid [52]. In consensus with these studies, we report that
HNK can significantly reduce the production of ROS in
LPS-stimulated microglial cells. However, the detailed
mechanisms of ROS inhibition by HNK in activated
microglia is not clearly understood. It would be interesting
to determine the mechanisms by which HNK mediates
these anti-oxidant activities.
Our studies further identify a crucial role for Klf4 in
mediating inflammation in BV-2 cells. We demonstrate
that overexpression of Klf4 increases the production of
iNOS and Cox-2 in these cells. In addition to these
observations, we also report that Klf4 overexpression
results in a decrease of anti-inflammatory activity of
HNK. In K-10 + LPS conditions, HNK was not able to
decrease the production of iNOS and Cox-2 significantly
with respect to the K-10 + LPS alone condition. In addi-
tion, the levels of iNOS as well as Cox-2 remained signifi-
cantly higher in the HNK treatment group with respect
to the LPS alone condition. It is likely that overexpressed
Klf4 remains bound to the respective promoter elements
in spite of HNK treatment to these cells. There is, how-
ever, some reduction observed when HNK treatment was
carried out in these Klf4 overexpressing cells which may
be due to HNK’s action on the basal level of cellular Klf4.
T h e s ef i n d i n g ss t r o n g l ys u g g e s tt h a tK l f 4i so n eo ft h e
key players of inflammation and therefore one of the key
targets of therapeutic intervention.
We hereby propose that Klf4 may be an important tar-
get for drugs that are known to traditionally block pNF-
B pathways. It would be interesting to understand the
molecular mechanisms of HNK-mediated Klf4 expres-
sion. Furthermore, Klf4 as a potential target for other
anti-inflammatory agents needs to be further evaluated.
Abbreviations
Bp: base pair; CBA: cytokine bead array; CNS: central nervous system; Cox-2:
cyclooxygenase-2; DAPI: 4,6-diamidino-2-phenylindole; DMEM: Dulbecco’s
modified Eagle’s medium; DMSO: dimethyl sulfoxide; FACS: fluorescence-
activated cell sorting; FBS: fetal bovine serum; HNK: honokiol; IL-6:
interleukin-6; iNOS: inducible nitric oxide synthase; kb: kilobase; Klf4: Krüppel-
like factor 4; K-10: pcDNA3.1-Klf4 construct; Lac-Z: pcDNA3.1-LacZ construct;
LPS: lipopolysaccharide; MCP-1: macrophage chemoattractant protein-1; MFI:
mean fluorescent intensity; NO: nitric oxide; PBS: phosphate-buffered saline;
pNF-κB: phospho-nuclear factor kappa B; ROS: reactive oxygen species; SEM:
standard error of the mean; siRNA: small interfering RNA; TNFα: tumor
necrosis factor alpha; 1X PBST: 1X PBS-Tween-20.
Acknowledgements
This work was supported by a core grant from the Department of
Biotechnology to the National Brain Research Centre and Life Science
Research Board, Defence Research & Developmental Organization (DLS/81/
48222/LSRB-213/EPB2010), Government of India and also supported by a
National Bioscience Award for Career Development from the Department of
Biotechnology to AB. DKK is the recipient of a Senior Research Fellowship
from the Indian Council of Medical Research, Government of India. The
authors thank Mr Manish Dogra for excellent technical assistance.
Authors’ contributions
DKK designed and performed the experiments, analyzed the data and
drafted the manuscript. RM, KK and MG performed the experiments. AB
participated in the design and coordination of the experiments. All the
authors reviewed the data and contributed to the preparation of the
manuscript. All the authors have read and approved the final version of the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 15 December 2011 Accepted: 19 March 2012
Published: 19 March 2012
References
1. Carson MJ, Thrash JC, Lo D: Analysis of microglial gene expression:
identifying targets for CNS neurodegenerative and autoimmune disease.
Am J Pharmacogenomics 2004, 4:321-330.
2. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.
Trends Neurosci 1996, 19:312-318.
3. Lund S, Christensen KV, Hedtjarn M, Mortensen AL, Hagberg H, Falsig J,
Hasseldam H, Schrattenholz A, Porzgen P, Leist M: The dynamics of the
LPS triggered inflammatory response of murine microglia under
different culture and in vivo conditions. J Neuroimmunol 2006, 180:71-87.
4. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT:
Systemic LPS causes chronic neuroinflammation and progressive
neurodegeneration. Glia 2007, 55:453-462.
5. Rhee SH, Hwang D: Murine TOLL-like receptor 4 confers
lipopolysaccharide responsiveness as determined by activation of NF
kappa B and expression of the inducible cyclooxygenase. J Biol Chem
2000, 275:34035-34040.
6. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS: Molecular
mechanisms underlying chemopreventive activities of anti-inflammatory
phytochemicals: down-regulation of COX-2 and iNOS through
suppression of NF-kappa B activation. Mutat Res 2001, 480-481:243-268.
7. Brown GC, Neher JJ: Inflammatory neurodegeneration and mechanisms
of microglial killing of neurons. Mol Neurobiol 2010, 41:242-247.
8. Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease. Nat
Rev Neurol 2010, 6:193-201.
9. Carson MJ: Microglia as liaisons between the immune and central
nervous systems: functional implications for multiple sclerosis. Glia 2002,
40:218-231.
10. Kim YS, Joh TH: Microglia, major player in the brain inflammation: their
roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 2006,
38:333-347.
11. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW,
Gerzsten RE, Edelman ER, Jain MK: Kruppel-like factor 4 regulates
endothelial inflammation. J Biol Chem 2007, 282:13769-13779.
12. Feinberg MW, Cao Z, Wara AK, Lebedeva MA, Senbanerjee S, Jain MK:
Kruppel-like factor 4 is a mediator of proinflammatory signaling in
macrophages. J Biol Chem 2005, 280:38247-38258.
13. Yoon HS, Chen X, Yang VW: Kruppel-like factor 4 mediates p53-
dependent G1/S cell cycle arrest in response to DNA damage. J Biol
Chem 2003, 278:2101-2105.
14. Liu J, Liu Y, Zhang H, Chen G, Wang K, Xiao X: KLF4 promotes the
expression, translocation, and release of HMGB1 in RAW264.7
macrophages in response to LPS. Shock 2008, 30:260-266.
Kaushik et al. Journal of Neuroinflammation 2012, 9:57
http://www.jneuroinflammation.com/content/9/1/57
Page 14 of 1515. Shen B, Smith RS Jr, Hsu YT, Chao L, Chao J: Kruppel-like factor 4 is a
novel mediator of Kallistatin in inhibiting endothelial inflammation via
increased endothelial nitric-oxide synthase expression. J Biol Chem 2009,
284:35471-35478.
16. Alder JK, Georgantas RW, Hildreth RL, Kaplan IM, Morisot S, Yu X,
McDevitt M, Civin CI: Kruppel-like factor 4 is essential for inflammatory
monocyte differentiation in vivo. J Immunol 2008, 180:5645-5652.
17. Segre JA, Bauer C, Fuchs E: Klf4 is a transcription factor required for
establishing the barrier function of the skin. Nat Genet 1999, 22:356-360.
18. Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW,
Kaestner KH: The zinc-finger transcription factor Klf4 is required for
terminal differentiation of goblet cells in the colon. Development 2002,
129:2619-2628.
19. Kaushik DK, Gupta M, Das S, Basu A: Kruppel-like factor 4, a novel
transcription factor regulates microglial activation and subsequent
neuroinflammation. J Neuroinflammation 2010, 7:68.
20. Shen CC, Ni CL, Shen YC, Huang YL, Kuo CH, Wu TS, Chen CC: Phenolic
constituents from the stem bark of Magnolia officinalis. J Nat Prod 2009,
72:168-171.
21. Lin YR, Chen HH, Ko CH, Chan MH: Neuroprotective activity of honokiol
and magnolol in cerebellar granule cell damage. Eur J Pharmacol 2006,
537:64-69.
22. Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J,
Wang N, Peng C, Zhao X, Wei Y, Chen L: Honokiol crosses BBB and
BCSFB, and inhibits brain tumor growth in rat 9 L intracerebral
gliosarcoma model and human U251 xenograft glioma model. PLoS One
2011, 6:e18490.
23. Fried LE, Arbiser JL: Honokiol, a multifunctional antiangiogenic and
antitumor agent. Antioxid Redox Signal 2009, 11:1139-1148.
24. Lin YR, Chen HH, Ko CH, Chan MH: Effects of honokiol and magnolol on
acute and inflammatory pain models in mice. Life Sci 2007, 81:1071-1078.
25. Lee SY, Cho JY: Inhibitory effects of honokiol on LPS and PMA-induced
cellular responses of macrophages and monocytes. BMB Rep 2009,
42:574-579.
26. Li CY, Chao LK, Wang SC, Chang HZ, Tsai ML, Fang SH, Liao PC, Ho CL,
Chen ST, Cheng WC, Chiang CS, Kuo YH, Hua KF, Hsu IC: Honokiol inhibits
LPS-induced maturation and inflammatory response of human
monocyte-derived dendritic cells. J Cell Physiol 2011, 226:2338-2349.
27. Chao LK, Liao PC, Ho CL, Wang EI, Chuang CC, Chiu HW, Hung LB, Hua KF:
Anti-inflammatory bioactivities of honokiol through inhibition of protein
kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway
to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem
2011, 58:3472-3478.
28. Weng TI, Wu HY, Kuo CW, Liu SH: Honokiol rescues sepsis-associated
acute lung injury and lethality via the inhibition of oxidative stress and
inflammation. Intensive Care Med 2011, 37:533-541.
29. Li J, Shao X, Wu L, Feng T, Jin C, Fang M, Wu N, Yao H: Honokiol: an
effective inhibitor of tumor necrosis factor-alpha-induced up-regulation
of inflammatory cytokine and chemokine production in human synovial
fibroblasts. Acta Biochim Biophys Sin (Shanghai) 2011, 43:380-386.
30. Wu F, Zhang W, Li L, Zheng F, Shao X, Zhou J, Li H: Inhibitory effects of
honokiol on lipopolysaccharide-induced cellular responses and signaling
events in human renal mesangial cells. Eur J Pharmacol 2011,
654:117-121.
31. Munroe ME, Businga TR, Kline JN, Bishop GA: Anti-inflammatory effects of
the neurotransmitter agonist honokiol in a mouse model of allergic
asthma. J Immunol 2010, 185:5586-5597.
32. Chiang CK, Sheu ML, Hung KY, Wu KD, Liu SH: Honokiol, a small molecular
weight natural product, alleviates experimental mesangial proliferative
glomerulonephritis. Kidney Int 2006, 70:682-689.
33. Mishra MK, Ghosh D, Duseja R, Basu A: Antioxidant potential of
minocycline in Japanese Encephalitis Virus infection in murine
neuroblastoma cells: correlation with membrane fluidity and cell death.
Neurochem Int 2009, 54:464-470.
34. Perrella MA, Patterson C, Tan L, Yet SF, Hsieh CM, Yoshizumi M, Lee ME:
Suppression of interleukin-1beta-induced nitric-oxide synthase
promoter/enhancer activity by transforming growth factor-beta1 in
vascular smooth muscle cells. Evidence for mechanisms other than NF-
kappaB. J Biol Chem 1996, 271:13776-13780.
35. Pathak SK, Bhattacharyya A, Pathak S, Basak C, Mandal D, Kundu M, Basu J:
Toll-like receptor 2 and mitogen- and stress-activated kinase 1 are
effectors of Mycobacterium avium-induced cyclooxygenase-2 expression
in macrophages. J Biol Chem 2004, 279:55127-55136.
36. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A:
Proinflammatory mediators released by activated microglia induces
neuronal death in Japanese encephalitis. Glia 2007, 55:483-496.
37. Eugenin EA, Berman JW: Chemokine-dependent mechanisms of
leukocyte trafficking across a model of the blood-brain barrier. Methods
2003, 29:351-361.
38. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv
Immunol 1993, 54:1-78.
39. Kishimoto T: Interleukin-6 and its receptor in autoimmunity. J Autoimmun
1992, 5(Suppl A):123-132.
40. Chen CM, Liu SH, Lin-Shiau SY: Honokiol, a neuroprotectant against
mouse cerebral ischaemia, mediated by preserving Na+, K + -ATPase
activity and mitochondrial functions. Basic Clin Pharmacol Toxicol 2007,
101:108-116.
41. Brown GC, Cooper CE: Nanomolar concentrations of nitric oxide
reversibly inhibit synaptosomal respiration by competing with oxygen at
cytochrome oxidase. FEBS Lett 1994, 356:295-298.
42. Iadecola C, Zhang F: Permissive and obligatory roles of NO in
cerebrovascular responses to hypercapnia and acetylcholine. Am J
Physiol 1996, 271:R990-R1001.
43. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1996,
1299:125-140.
44. Mestre JR, Mackrell PJ, Rivadeneira DE, Stapleton PP, Tanabe T, Daly JM:
Redundancy in the signaling pathways and promoter elements
regulating cyclooxygenase-2 gene expression in endotoxin-treated
macrophage/monocytic cells. J Biol Chem 2001, 276:3977-3982.
45. Caivano M, Cohen P: Role of mitogen-activated protein kinase cascades
in mediating lipopolysaccharide-stimulated induction of
cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol
2000, 164:3018-3025.
46. Shen S, Yu S, Binek J, Chalimoniuk M, Zhang X, Lo SC, Hannink M, Wu J,
Fritsche K, Donato R, Sun GY: Distinct signaling pathways for induction of
type II NOS by IFNgamma and LPS in BV-2 microglial cells. Neurochem
Int 2005, 47:298-307.
47. Kim BH, Cho JY: Anti-inflammatory effect of honokiol is mediated by
PI3K/Akt pathway suppression. Acta Pharmacol Sin 2008, 29:113-122.
48. Matsuda H, Kageura T, Oda M, Morikawa T, Sakamoto Y, Yoshikawa M:
Effects of constituents from the bark of Magnolia obovata on nitric
oxide production in lipopolysaccharide-activated macrophages. Chem
Pharm Bull(Tokyo) 2001, 49:716-720.
49. Kim KR, Park KK, Chun KS, Chung WY: Honokiol inhibits the progression of
collagen-induced arthritis by reducing levels of pro-inflammatory
cytokines and matrix metalloproteinases and blocking oxidative tissue
damage. J Pharmacol Sci 2010, 114:69-78.
50. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: The anti-inflammatory effect
of honokiol on neutrophils: mechanisms in the inhibition of reactive
oxygen species production. Eur J Pharmacol 2003, 475:19-27.
51. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: Honokiol protects rat brain
from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil
infiltration and reactive oxygen species production. Brain Res 2003,
992:159-166.
52. Cui HS, Huang LS, Sok DE, Shin J, Kwon BM, Youn UJ, Bae K: Protective
action of honokiol, administered orally, against oxidative stress in brain
of mice challenged with NMDA. Phytomedicine 2007, 14:696-700.
doi:10.1186/1742-2094-9-57
Cite this article as: Kaushik et al.: Therapeutic targeting of Krüppel-like
factor 4 abrogates microglial activation. Journal of Neuroinflammation
2012 9:57.
Kaushik et al. Journal of Neuroinflammation 2012, 9:57
http://www.jneuroinflammation.com/content/9/1/57
Page 15 of 15